By David Balto
This summer, lawmakers missed a big chance to lower the cost of prescription medicine.
Despite including a host of new drug-pricing measures in the Inflation Reduction Act (IRA), legislators did almost nothing to crack down on some of the worst actors in the entire healthcare system — the “pharmacy benefit managers” and other supply-chain intermediaries who routinely raise drug costs and deny consumers access to life saving drugs.
Controlling drug costs is a necessary concern and the IRA tries to achieve this by imposing price controls on some drugs purchased by Medicare. But this is far less than a half a loaf solution. It doesn’t control costs in commercial markets and, more importantly, does nothing to address drug market intermediaries that are inflating the cost of drugs.
It’s easy to target drug manufacturers. But in the past several years we have come to realize that drug middlemen, known as pharmacy benefit managers, are actively inflating the cost of drugs.
PBMs arose to perform a specific task: Negotiate with drug makers on behalf of insurance companies over the price of medicine. In theory, PBMs should be motivated to drive hard bargains, and thus save consumers money.
But in practice, the top three PBMs each own, or are owned by, the country’s three largest insurance companies — and also own their own pharmacies. They thus have a vested interest in driving traffic to their other lines of business. That squashes rather than encourages competition,
increasing the price of drugs for consumers.
Moreover, the sheer market power of the big three — CVS Caremark, Optum Rx, and Express Scripts, with a combined market share greater than 80% — has forced smaller community pharmacies into accepting below-cost reimbursement, and put many out of business.
PBMs are also hurting patients in more direct ways.
Drug companies provide PBMs rebates in exchange for PBMs including those medicines on insurance-plan formularies.
While PBMs were originally formed to act as honest brokers and pass these savings on, today, they keep a significant portion of the funds for themselves — with no legal limit. Moreover, their profits rise when drug prices are higher. So they have incentive to seek steeper, not lower, prices.
That creates an incentive for PBMs to demand higher and higher rebates to pad their own bottom lines, which puts upward pressure on list prices. In essence, PBMs behave like realtors who show clients overpriced houses just so they can get higher commissions.
But it’s not just a question of higher prices. Often PBMs exclude drugs that are more effective in treating critical diseases or they exclude lower cost generics. Other times they impose difficult step therapy programs which require patients to continue to take drugs that do not work, before they can get the more efficacious drug — disfavored because it doesn’t offer a higher rebate.
Unsurprisingly, consumers and community pharmacies are up in arms. Over 24,000 consumers and community pharmacists filed comments with the Federal Trade Commission this year asking for a thorough study of PBM practices.
Concern over healthcare costs animated much of the debate that led to passage of the IRA. Yet pharmacy benefit managers emerged from the process virtually unscathed. Hopefully, lawmakers will soon change that.
David Balto is a public interest antitrust attorney and is the former Policy Director of the Federal Trade Commission. This piece originally ran in RealClearPolicy.